November 13th, 2026ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand EczemaExperts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.Read more
November 11th, 2026Dupilumab May Slow Atopic March in Atopic Dermatitis: Meta-AnalysisDupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.Read more
November 10th, 2026Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MDEmma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.Read more
November 18th, 2026What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next. Read more
November 18th, 2026Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics. Read more
November 18th, 2026RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPFPooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.Read more
November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more